Simpson Thacher Advises the Underwriters on Berkshire Hathaway’s Largest Ever Debt Offering, Totaling $12 Billion in U.S. Dollar-Denominated and Euro-Denominated Notes

Wednesday, March 16, 2016

Simpson Thacher represented BofA Merrill Lynch, Goldman, Sachs & Co., J.P. Morgan and Wells Fargo Securities in the registered public offerings by Berkshire Hathaway Inc. (“Berkshire”) and Berkshire Hathaway Finance Corporation (“BHFC”) of $12 billion aggregate principal amount of notes over ten tranches with maturities ranging from 2 to 12 years. The transaction included offerings by Berkshire of $5.5 billion in U.S. dollar-denominated notes and €2.75 billion ($3.05 billion) in euro-denominated notes, as well as BHFC’s offering of $3.5 billion in both fixed and floating rate notes which will be guaranteed by Berkshire. All transactions closed on March 15, 2016. Berkshire’s euro-denominated notes will be listed on the New York Stock Exchange. More >>

Tags:  Simpson Thacher & Bartlett LLP | New York

Distinguished FDA Lawyer Moves to McDermott

Tuesday, March 15, 2016

McDermott Will & Emery announced today that distinguished life sciences lawyer Vernessa Pollard has joined the Firm as co-head of its Food and Drug Administration (FDA) practice in Washington, DC.

Ms. Pollard comes to McDermott from another AmLaw 100 firm, where she advised clients on regulatory, compliance, and legislative matters involving medical devices, pharmaceuticals, digital health applications, health information technology, and other products. She formerly served as Associate Chief Counsel for Enforcement in the Office of Chief Counsel at the FDA for six years. More >>

Tags:  McDermott Will & Emery LLP | Washington